{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T06:53:05Z","timestamp":1772347985376,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Millenium Pharmaceuticals, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2019,10,29]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Ixazomib-revlimid-dexamethason showed significant activity in relapsed\/refractory multiple myeloma (RRMM). Here, we evaluate ixazomib in combination with thalidomide and dexamethasone for induction treatment followed by ixazomib maintenance therapy in RRMM patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ninety patients have been included. Ixazomib\u2013thalidomide\u2013dexamethasone (4\u2009mg, day 1, 8, 15; 100\u2009mg daily; and 40\u2009mg weekly) was scheduled for eight cycles followed by maintenance with ixazomib for one year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The overall response rate was 51.1%, 23.3% achieved CR or VGPR and 10% MR resulting in a clinical benefit rate of 61.1%. In patients completing \u22652 cycles, the rates were 60.5%, 27.6% and 68.4%, respectively. Median progression-free survival (PFS) was 8.5 months in all, and 9.4 months in those completing \u22652 cycles. Response rates, PFS and overall survival (OS) were similar in patients with and without t(4;14) and\/or del(17p), but PFS and OS was significantly shorter in patients with gain of 1q21. Multivariate regression analysis revealed gain of 1q21 as the most important factor associated with OS. Ixazomib maintenance resulted in an upgrade in the depth of response in 12.4% of patients. Grade 3\/4 toxicities were relatively rare.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Ixazomib\u2013thalidomide\u2013dexamethasone followed by ixazomib maintenance therapy is active and well tolerated in patients with RRMM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration number<\/jats:title><jats:p>NCT02410694<\/jats:p><\/jats:sec>","DOI":"10.1038\/s41416-019-0581-8","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T23:42:28Z","timestamp":1569541348000},"page":"751-757","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Ixazomib\u2013Thalidomide\u2013Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfram","family":"Poenisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Lechner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eberhard","family":"Gunsilius","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl Jochen","family":"Krenosz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Weisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietger","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Willenbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Zojer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"581_CR1","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","volume":"15","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K., Berdeja, J. G., Niesvizky, R., Lonial, S., Laubach, J. P., Hamadani, M. et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study. Lancet Oncol. 15, 1503\u20131512 (2014).","journal-title":"Lancet Oncol."},{"key":"581_CR2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel, D. S., Martin, T., Wang, M., Vij, R., Jakubowiak, A. J., Lonial, S. et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 120, 2817\u20132825 (2012).","journal-title":"Blood."},{"issue":"10","key":"581_CR3","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/17474086.2018.1518129","volume":"11","author":"Saurabh Zanwar","year":"2018","unstructured":"Zanwar S., Abeykoon J. P., Kapoor P. Ixazomib: a novel drug for multiple myeloma. Expert. Rev. Hematol. 10, 761\u2013771 (2018)","journal-title":"Expert Review of Hematology"},{"key":"581_CR4","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","volume":"124","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K., Bensinger, W. I., Zimmerman, T. M., Reeder, C. B., Berenson, J. R., Berg, D. et al. Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma. Blood. 124, 1047\u20131055 (2014).","journal-title":"Blood."},{"key":"581_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.60","volume":"5","author":"SK Kumar","year":"2015","unstructured":"Kumar, S. K., LaPlant, B., Roy, V., Reeder, C. B., Lacy, M. Q., Gertz, M. A. et al. Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib. Blood Cancer J. 5, e338 (2015).","journal-title":"Blood Cancer J."},{"key":"581_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s11523-017-0504-7","volume":"12","author":"ZT Al-Salama","year":"2017","unstructured":"Al-Salama, Z. T., Garnock-Jones, K. P. & Scott, L. J. Ixazomib: a review in relapsed and\/or refractory multiple myeloma. Target Oncol. 12, 535\u2013542 (2017).","journal-title":"Target Oncol."},{"key":"581_CR7","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P., Avet-Loiseau, H., Lonial, S., Usmani, S., Siegel, D., Anderson, K. C. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 127, 2955\u20132962 (2016).","journal-title":"Blood."},{"issue":"Suppl 1","key":"581_CR8","doi-asserted-by":"publisher","first-page":"800-","DOI":"10.1182\/blood-2018-99-111650","volume":"132","author":"S Zweegman","year":"2018","unstructured":"Zweegman, S., Schjesvold, F. H., van der Holt, B., Levin, M.-D., Stege, C. A. M., Waage, A. et al. Ixazomib-thalidomide-low dose dexamethasone (ITd) induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126\/Nmsg 21#13 Trial. Blood. 132(Suppl 1), 800 (2018).","journal-title":"Blood."},{"key":"581_CR9","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ejca.2018.09.011","volume":"106","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A., Grosicki, S., Jedrzejczak, W. W., Nahi, H., Gruber, A., Hansson, M. et al. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. Eur J Cancer. 106, 89\u201398 (2018).","journal-title":"Eur J Cancer."},{"key":"581_CR10","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P., Masszi, T., Grzasko, N., Bahlis, N. J., Hansson, M., Pour, L. et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 374, 1621\u20131634 (2016).","journal-title":"N Engl J Med."},{"key":"581_CR11","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1182\/blood-2017-06-791228","volume":"130","author":"H Avet-Loiseau","year":"2017","unstructured":"Avet-Loiseau, H., Bahlis, N. J., Chng, W. J., Masszi, T., Viterbo, L., Pour, L. et al. Ixazomib significantly prolongs progression-free survival in high-risk relapsed\/refractory myeloma patients. Blood. 130, 2610\u20132618 (2017).","journal-title":"Blood."},{"issue":"Suppl 1","key":"581_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2018-99-112079","volume":"132","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A., Gay, F., Schjesvold, F. H., Beksac, M., Hajek, R., Weisel, K. et al. Maintenance therapy with the oral proteasome inhibitor (PI) ixazomib significantly prolongs progression-free survival (PFS) following autologous stem cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM): phase 3 tourmaline-MM3 trial. Blood. 132(Suppl 1), 301 (2018).","journal-title":"Blood."},{"key":"581_CR13","doi-asserted-by":"crossref","unstructured":"Perrot, A., Corre, J. & Avet-Loiseau, H. Risk stratification and targets in multiple myeloma: from genomics to the bedside. Am Soc Clin Oncol Educ Book. 38, 675\u2013680 (2018)","DOI":"10.1200\/EDBK_200879"},{"key":"581_CR14","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S. K. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 125, 2068\u20132074 (2015).","journal-title":"Blood."},{"key":"581_CR15","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457\u2013481 (1958).","journal-title":"J. Am. Stat. Assoc."},{"key":"581_CR16","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/bmj.328.7447.1073","volume":"328","author":"JM Bland","year":"2004","unstructured":"Bland, J. M. & Altman, D. G. The logrank test. BMJ. 328, 1073 (2004).","journal-title":"BMJ."},{"key":"581_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2307\/2342435","volume":"98","author":"RA Fisher","year":"1935","unstructured":"Fisher, R. A. The logic of inductive inference. J. Royal Stat. Soc. 98, 39\u201382 (1935).","journal-title":"J. Royal Stat. Soc."},{"key":"581_CR18","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"Cox DR. Regression Models and Life-Tables.","year":"1972","unstructured":"Cox DR. Regression Models and Life-Tables. J. Royal Stat. Soc. Ser. B (Methodol.) 34, 187\u2013220 (1972).","journal-title":"J. Royal Stat. Soc. Ser. B (Methodol.)"},{"issue":"Suppl 1","key":"581_CR19","doi-asserted-by":"publisher","first-page":"255-","DOI":"10.1182\/blood-2018-99-112116","volume":"132","author":"G Cook","year":"2018","unstructured":"Cook, G., Parrish, C., Yong, K., Cavenagh, J., Snowden, J. A., Drayson, M. T. et al. Ixazomib, thalidomide and dexamethasone is an effective and well tolerated re-induction regimen leading to salvage autologous stem cell transplantation (sASCT): results from the re-induction interim analysis of UK-MRA myeloma XII (ACCoRD) trial. Blood. 132(Suppl 1), 255 (2018).","journal-title":"Blood."},{"key":"581_CR20","doi-asserted-by":"crossref","unstructured":"Krishnan A., Kapoor P., Palmer J. M., Tsai N. C., Kumar S., Lonial S., et al. Phase I\/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed\/refractory multiple myeloma. Leukemia. 32, 1567\u20131574 (2018).","DOI":"10.1038\/s41375-018-0038-8"},{"key":"581_CR21","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/bjh.15679","volume":"184","author":"SK Kumar","year":"2019","unstructured":"Kumar, S. K., Grzasko, N., Delimpasi, S., Jedrzejczak, W. W., Grosicki, S., Kyrtsonis, M. C. et al. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Br. J. Haematol. 184, 536\u2013546 (2019).","journal-title":"Br. J. Haematol."},{"key":"581_CR22","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","volume":"127","author":"RC Baz","year":"2016","unstructured":"Baz, R. C., Martin, T. G. 3rd, Lin, H. Y., Zhao, X., Shain, K. H., Cho, H. J. et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood. 127, 2561\u20132568 (2016).","journal-title":"Blood."},{"key":"581_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari, A., Suvannasankha, A., Fay, J. W., Arnulf, B., Kaufman, J. L., Ifthikharuddin, J. J. et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 130, 974\u2013981 (2017).","journal-title":"Blood."},{"key":"581_CR24","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A., Dytfeld, D., Grosicki, S., Moreau, P., Takezako, N., Hori, M. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379, 1811\u20131822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"581_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., Hajek, R. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"581_CR26","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A., Chanan-Khan, A., Weisel, K., Nooka, A. K., Masszi, T., Beksac, M. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"581_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ejh.12546","volume":"96","author":"H Nahi","year":"2016","unstructured":"Nahi, H., Vatsveen, T. K., Lund, J., Heeg, B. M., Preiss, B., Alici, E. et al. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21. Eur. J. Haematol. 96, 46\u201354 (2016).","journal-title":"Eur. J. Haematol."},{"key":"581_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2016.1272684","volume":"58","author":"N Grzasko","year":"2017","unstructured":"Grzasko, N., Hajek, R., Hus, M., Chocholska, S., Morawska, M., Giannopoulos, K. et al. Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group. Leuk. Lymphoma 58, 1\u201315 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"581_CR29","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1182\/blood-2006-03-009910","volume":"108","author":"I Hanamura","year":"2006","unstructured":"Hanamura, I., Stewart, J. P., Huang, Y., Zhan, F., Santra, M., Sawyer, J. R. et al. Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplantation. Blood. 108, 1724\u20131732 (2006).","journal-title":"Blood."},{"key":"581_CR30","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","volume":"118","author":"JD Shaughnessy Jr.","year":"2011","unstructured":"Shaughnessy, J. D. Jr., Qu, P., Usmani, S., Heuck, C. J., Zhang, Q., Zhou, Y. et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 118, 3512\u20133524 (2011).","journal-title":"Blood."},{"key":"581_CR31","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1182\/blood-2006-07-038703","volume":"109","author":"F Zhan","year":"2007","unstructured":"Zhan, F., Colla, S., Wu, X., Chen, B., Stewart, J. P., Kuehl, W. M. et al. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 109, 4995\u20135001 (2007).","journal-title":"Blood."},{"key":"581_CR32","doi-asserted-by":"publisher","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","volume":"19","author":"GJ Morgan","year":"2013","unstructured":"Morgan, G. J., Davies, F. E., Gregory, W. M., Bell, S. E., Szubert, A. J., Cook, G. et al. Long-term follow-up of MRC Myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment. Clin. Cancer Res. 19, 6030\u20136038 (2013).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"581_CR33","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1016\/j.clml.2018.08.005","volume":"19","author":"Roberto Jos\u00e9 Pessoa de Magalh\u00e3es Filho","year":"2019","unstructured":"Pessoa de Magalhaes Filho R. J., Crusoe E., Riva E., Bujan W., Conte G., Navarro Cabrera J. R., et al. Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in latin american countries. Clin. lymphoma Myeloma Leuk. 19, e43\u2013e50 (2019).","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"key":"581_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3389\/fnmol.2015.00077","volume":"8","author":"RH Shih","year":"2015","unstructured":"Shih, R. H., Wang, C. Y. & Yang, C. M. NF-kappaB signaling pathways in neurological inflammation: a mini review. Front. Mol. Neurosci. 8, 77 (2015).","journal-title":"Front. Mol. Neurosci."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0581-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0581-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-019-0581-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T03:35:57Z","timestamp":1721792157000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-019-0581-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,10,29]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1038\/s41416-019-0581-8","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.L.: research funding: Takeda, Amgen; Speaker\u2019s Bureau: Takeda, Amgen, Janssen, BMS, Celgene; Consultancy Fees: PharmaMar; S.K.: Consultancy Fees: Takeda; E.G.: Honoraria: Takeda, Janssen, Amgen, BMS; Advisory Board: Takeda, Janssen, Amgen, Novartis; A.P.: Honoraria, Advisory Board: Takeda, Celgene; K.W.: Honoraria: Novartis, Janssen, Celgene, Amgen, Onyx, Takeda, BMS; Consultancy Fees: Janssen, Celgene, Amgen, BMS, Takeda, Onyx; R.G.: Research Funding: Roche, Celgene, Takeda, Novartis; Personal Fees: Roche, Takeda, BMS, Amgen; H.E.: Speaker\u2019s Bureau, Advisory Board: Celgene, Janssen, Amgen, BMS, Novartis; Consultancy Fees, Honoraria: Celgene, Janssen, BMS, Amgen; W.W.: Research Funding: Amgen, BMS, Celgene, Janssen, Novartis, Roche, Takeda; Advisory Board\/Consultancy fees: Amgen, BMS, Celgene, Janssen, Novartis, Pfizer, Roche, Sandoz, Takeda; T.M.: Honoraria: Takeda. NZ.: Honoraria: Janssen, Celgene, Takeda, Amgen. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study has been conducted according to the principles of the declaration of Helsinki 2008. Ethical approval has been granted from all ethical committees responsible for all participating study sites including the ethical committee of the city of Vienna for Austria, the ethical committee of the medical faculty of Leipzig for Germany, and the central ethics committee of the ministry of health for Czech Republic. All patients signed an informed consent for participating in this trial, including the option of publication of the data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This work has been supported by a research grant of Takeda.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The data are available for all study authors. The datasets used and analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}